Endpoints News
WHO advises against GLP-1s for younger kids Read in browser
Endpoints News
Thank you for reading, Test Researcher!
basic
UPGRADE
M T Wed Th F
7 October, 2026
PARTNER OF CHOICE FOR BIOLOGICS MANUFACTURING
Avid Bioservices is the partner of choice for biologics innovators seeking scientific expertise, operational excellence, and reliable execution from clinic to commercial.
sponsored by Avid Bioservices, Inc.
presented by iRegene
iRe­gene Ther­a­peu­tics’s Nou­vSight001 Cleared for Clin­i­cal Tri­als in the U.S. and Chi­na for Re­tini­tis Pig­men­tosa
top stories
1. PhRMA sues Trump administration over GLOBE drug pricing demo program
2. WHO advises against obesity drugs for younger children
3. Zuckerberg's Biohub expands virtual cell effort to $1.8B, looping in Isomorphic, Meta, Google
4. Dutch court blocks subcutaneous Keytruda in eight European countries
5. Ultragenyx sells PRV for $210M and still has another voucher it plans to monetize
6. Vaccine for deadly brain cancer narrowly misses goal in key trial
7. Updated: CAR-T biotech Caribou to pull the plug after struggling to find funding
more stories
• 
Nicole DeFeudis
.

A federal appeals court heard arguments yesterday over the Trump administration’s reconstitution of ACIP, the CDC’s vaccine advisory panel. A Massachusetts federal judge suspended the appointments of 13 new panel members in March, after determining that there was a “substantial likelihood” the appointments were unlawful. ACIP has effectively remained frozen since. A decision from the appeals court could come any day now.
.
Nicole DeFeudis
Senior Reporter, Endpoints News
@Nicole_DeFeudis
On Wednesday, the drug industry\'s major trade group sued the government over CMS\' GLOBE drug pricing program. (AP Photo/Jacquelyn Martin)
1
by Max Bayer

The phar­ma in­dus­try is yet again tak­ing the gov­ern­ment to court over its lat­est ef­fort to con­trol US drug prices.

Last week, the Trump ad­min­is­tra­tion...

Read the full story
2
by Maggie Fick

The World Health Or­ga­ni­za­tion on Wednes­day rec­om­mend­ed against GLP-1 drugs for chil­dren un­der 10 with obe­si­ty and said ado­les­cents ages 10 to 19 should re­ceive them...

Read the full story
3
by Andrew Dunn

Tech gi­ants and US gov­ern­ment agen­cies are fund­ing an am­bi­tious ef­fort to build AI mod­els to pre­dict cel­lu­lar be­hav­ior and broad­er bi­ol­o­gy.

With $1.8 bil­lion...

Read the full story
4
by Nicole DeFeudis

A Dutch court has or­dered Mer­ck to stop man­u­fac­tur­ing and sell­ing its in­jectable for­mu­la­tion of Keytru­da in eight Eu­ro­pean coun­tries.

The court ruled that Mer­ck...

Read the full story
5
by Kyle LaHucik

Ul­tragenyx Phar­ma­ceu­ti­cal is sell­ing a pri­or­i­ty re­view vouch­er to an undis­closed buy­er for $210 mil­lion, mark­ing one of the rich­est sales of the speedy-ap­proval...

Read the full story
AI Day 2026 - October 14
Workforces restructured, AI-designed drugs in the clinic, record money chasing unknown potential, the transformation is already underway. Where does biopharma stand now? Register free for the virtual program and get the scoop.